logo-loader
ImmuPharma PLC

2019 Annual General Meeting

/**/ p{margin-top:0cm;margin-right:0cm;margin-bottom:7.5pt;margin-left:0cm;line-height:13.5pt;font-size:8.5pt;font-family:"Times New Roman","serif";color:#666666;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .ag{size:612.0pt 792.0pt;margin:72.0pt 90.0pt 72.0pt 90.0pt;}div.ag{}p.bg{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}span.be{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.bh{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: justify}span.bc{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.bi{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align:justify}span.ba{font-size: 11.0pt;font-family:"Calibri","sans-serif"}p.bj{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext; font-weight: bold; text-align: center}span.ay{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} p.bk{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext; text-align: center}p.bl{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: center}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;}span.au{font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight:normal}p.o,li.o,div.o{margin-right:0cm;margin-left:0cm;line-height:normal;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;}span.p{}table.bm{width:606.25pt;margin-left:-10.8pt;border-collapse:collapse}td.ai{width:595.45pt;padding:0cm 5.4pt 0cm 5.4pt}span.at{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}table.bn{width:18.0cm;border-collapse:collapse} td.ar{width:294.0pt;padding:0cm 5.4pt 0cm 5.4pt}a.as{font-weight: bold}td.aq{width:194.7pt;padding:0cm 5.4pt 0cm 5.4pt}span.ap{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}span.ao{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}span.bo{color:blue;font-size:11.0pt;font-family:"Calibri","sans-serif"; color:windowtext;text-decoration:none}p.bp{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-right:-5.4pt;text-align:justify}td.al{width:150.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.ak{border:none;padding:0cm 0cm 0cm 0cm} /**/
RNS Number : 6908D
Immupharma PLC
27 June 2019
 

 

 

 

                                                                                                                                                                      27 JUNE 2019

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

2019 ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.

-Ends-

 

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

 

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGMUBOURKVANUAR

Quick facts: ImmuPharma PLC

Price: £0.10

Market: AIM
Market Cap: £15.91 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Immupharma chairman details £2.66mln financing and open label extension study

ImmuPharma PLC’s (LON:IMM) chairman Tim McCarthy caught up with Proactive London's Andrew Scott to discuss the results of a follow-up study which was designed to evaluate Lupuzor’s safety and tolerability. McCarthy says the six month extension study confirmed its outstanding and robust...

on 4/7/19